SPARC succeeds in phase 3 trial of PDP-716 in glaucoma patients

SPARC succeeds in phase 3 trial of PDP-716 in glaucoma patients

Sun Pharma Advanced Research Company (SPARC) has succeeded in a phase 3 clinical trial for PDP-716 ophthalmic suspension, its investigational drug for the treatment of open angle glaucoma or ocular hypertension. The late-stage clinical trial met its pre-specified primary endpoint by showing that daily once dosing of PDP-716 is equivalent to Alphagan P 0.1% dosed […]